2Hudson LD. Monti CM. Rational and use of corticosteroids in chronic obstructive pulmonary disease. Med Clin North Am,1990,74:661. 被引量：1
3Szafranski W,Cukier A,Ramirez A,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 2003,21 (1): 74-81, 被引量：1
4Barnes P. Scientific rationale for inhaled combination therapy with long-acting β2-agonist and corticosteroids. Eur Respir J,2002,19(1): 182-191. 被引量：1
5Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucoorticoids and β2-agonist on bronchial airway smooth muscle cell through synchronized cellular signaling. Lancet, 2002,360(9342): 1293-1299. 被引量：1
6Senderovitz T, Vestbo J,Frandsen N,et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med, 1999,93(10):715-718. 被引量：1
7van Grunsven P, van Schayck C, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease:a meta analysis. Thorax,1999,54(1):7-14. 被引量：1
8Abdullah A,Sin DD,McAlister FA,et al. The Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A Systematic Review of Randomized Placebo-Controlled Trials.Am J Med,2002,113(1):59-65. 被引量：1
9Highland KB,Stvarge C,Heffaver JE,et al. Long-Term Effects of Inhaled Corticosteroids on FEV1 in Patients with Chronic Obstructive Pulmonary Disease. Ann Intern Med, 2003, 138(12) :969-973. 被引量：1
10Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflowlimitation in chronic obstructive pulmonary disease: a meta analysis. Thorax,2003,58(11) :937-941. 被引量：1
